Lido Advisors LLC Has $2.98 Million Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Lido Advisors LLC boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 34.8% in the 2nd quarter, Holdings Channel.com reports. The firm owned 5,672 shares of the biopharmaceutical company’s stock after buying an additional 1,464 shares during the quarter. Lido Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $2,978,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Norges Bank acquired a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at about $628,151,000. Nuveen LLC acquired a new stake in Regeneron Pharmaceuticals during the first quarter worth about $343,764,000. Acadian Asset Management LLC increased its stake in Regeneron Pharmaceuticals by 234.7% during the second quarter. Acadian Asset Management LLC now owns 465,740 shares of the biopharmaceutical company’s stock valued at $244,480,000 after acquiring an additional 326,583 shares during the period. Loomis Sayles & Co. L P raised its holdings in Regeneron Pharmaceuticals by 18.6% in the 2nd quarter. Loomis Sayles & Co. L P now owns 1,941,070 shares of the biopharmaceutical company’s stock valued at $1,019,062,000 after acquiring an additional 305,089 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its holdings in Regeneron Pharmaceuticals by 18.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,143,093 shares of the biopharmaceutical company’s stock valued at $724,984,000 after acquiring an additional 174,056 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Regeneron Pharmaceuticals

In related news, VP Jason Pitofsky sold 431 shares of the stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $651.43, for a total transaction of $280,766.33. Following the sale, the vice president directly owned 4,233 shares in the company, valued at $2,757,503.19. This represents a 9.24% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Christine A. Poon sold 6,500 shares of the firm’s stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total value of $4,252,755.00. Following the sale, the director directly owned 2,352 shares of the company’s stock, valued at $1,538,843.04. This represents a 73.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 7.02% of the stock is owned by insiders.

Analyst Ratings Changes

REGN has been the topic of several recent research reports. Bank of America lifted their price objective on Regeneron Pharmaceuticals from $543.00 to $627.00 and gave the stock an “underperform” rating in a report on Wednesday, October 29th. Hsbc Global Res upgraded shares of Regeneron Pharmaceuticals to a “strong-buy” rating in a research note on Monday, November 24th. UBS Group boosted their price target on shares of Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the company a “neutral” rating in a report on Friday, November 7th. Royal Bank Of Canada raised their price objective on shares of Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the stock a “sector perform” rating in a report on Wednesday, October 29th. Finally, Scotiabank upped their target price on shares of Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the company a “sector perform” rating in a research note on Monday, November 24th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, eight have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $757.91.

Regeneron Pharmaceuticals Stock Down 1.1%

Shares of NASDAQ REGN opened at $742.00 on Wednesday. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $800.99. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.06. The business has a fifty day moving average of $641.33 and a two-hundred day moving average of $585.78. The stock has a market cap of $77.98 billion, a PE ratio of 17.77, a PEG ratio of 2.03 and a beta of 0.37.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $9.73 by $2.10. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The business had revenue of $3.75 billion during the quarter, compared to analysts’ expectations of $3.57 billion. During the same quarter last year, the company posted $12.46 EPS. The firm’s revenue for the quarter was up .9% on a year-over-year basis. As a group, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, December 5th. Stockholders of record on Thursday, November 20th will be paid a $0.88 dividend. The ex-dividend date is Thursday, November 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is 8.43%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.